CRANBURY, N.J.--(BUSINESS WIRE)--Physicians’ Education Resource® (PER®), a worldwide leading resource for continuing medical education (CME), will conduct five CME-accredited satellite symposia during the 61st American Society of Hematology’s Annual Meeting and Exposition. The symposia will take place Friday, Dec. 6 at the Hyatt Regency Orlando and Rosen Centre Hotel in Orlando, Florida.
“We are once again thrilled for the opportunity to return to ASH’s annual meeting exposition and provide actionable education to hematologists,” said Phil Talamo, president of PER®. “Each symposium this year will offer attendees noteworthy insight on pivotal topics in the realm of hematology, including the primary hemophagocytic lymphohistiocytosis, the graft-versus-host-disease, adolescent and young adult and adult acute lymphoblastic leukemia, myeloproliferative neoplasms, and diffuse large b-cell lymphoma.”
The PER® satellite symposia are as follows:
- ASH: MPN Tumor Board: Application of Novel Agents for the Treatment of Polycythemia Vera and Myelofibrosis, which will be held from 7 to 10 p.m. at the Hyatt Regency Orlando in the Orlando Ballroom. The symposium will be chaired by Ronald Hoffman, M.D., Albert A. and Vera G. List professor of medicine, director, Myeloproliferative Disorders Research Program, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York. This live CME dinner program will describe current and emerging strategies for the management of patients with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV) and myelofibrosis (MF), in addition to appropriate strategies for identification of patients with varying risk levels of disease. To register, click here.
- ASH: Medical Crossfire®: Case Studies in AYA and Adult Acute Lymphoblastic Leukemia – How the Experts Think and Treat, which will be held from 1:30 to 4:30 p.m. at the Hyatt Regency Orlando in the Windermere Ballroom X. The symposium will be chaired by Elias Jabbour, M.D., professor of medicine, department of leukemia, The University of Texas MD Anderson Cancer Center in Houston. During the luncheon program, the unique treatment challenges among adolescent and young adult, and adult patients with acute lymphoblastic leukemia (ALL) will be dissected, specifically the advances in understanding ALL pathology, including evolving applications for cytogenetic and molecular abnormality characteristics. To register, click here.
- ASH: The Evolving Treatment Landscape for Patients With GvHD: More Options, More Decisions, Better Outcomes, which will be held from 7-10 p.m. at the Hyatt Regency Orlando in the Windermere Ballroom X. The symposium will be chaired by Corey S. Cutler, M.D., MPH, FRCPC, associate professor of medicine, Harvard Medical School, director, clinical research, stem cell transplantation, Dana-Farber Cancer Institute, both in Boston. The expert faculty of this dinner symposium will highlight unmet clinical needs and the most recent advances in both acute and chronic graft-versus-host-disease (GvHD), as well as present the most recent data pertaining to clinical activity of therapeutic agents in development, patient selection and management of treatment-related side effects in the GvHD settings. To register, click here.
- ASH: Primary HLH: Diagnosis, Management, and Treatment in the 21st Century, which will be held from 1:30-3:30 p.m. at the Rosen Centre Hotel in the Grand Ballroom DE. The symposium will be chaired by Michelle L. Hermiston, M.D., Ph.D., associate professor, department of pediatrics, UCSF School of Medicine, pediatric hematologist and oncologist, Benioff Children’s Hospital, University of California in San Francisco. During the luncheon symposium, the expert faculty panel will review the latest clinical data and ongoing clinical trials with the potential to affect the care of patients with hemophagocytic lymphohistiocytosis (HLH). Accredited by the To register, click here.
- ASH: Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL, which will be held from 1:30-4:30 p.m. at the Rosen Centre Hotel in Grand Ballroom C. The symposium will be chaired by Gilles A. Salles, M.D., Ph.D., professor of medicine and hematology, Claude Bernard University of Lyon, head of the department of hematology, Lyon-Sud University Hospital Complex in Pierre-Bénite, France. During the luncheon program, experts will provide their perspectives on managing challenges in treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). State-of-the-art approaches in risk classification and selection of therapy will be discussed, in addition to the role of stem-cell transplants. To register, click here.
About Physicians’ Education Resource® (PER®)
Since 1995, PER® has been dedicated to advancing cancer care through professional education and now advances patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER® initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas. While expanding into topics outside of oncology, PER® stands as the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. PER® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is a brand of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in the U.S. dedicated to delivering trusted health care news across multiple channels.
